nach oben

Calcified Tissue International

Erschienen in:

13.04.2020 | Review

The Causes of Hypo- and Hyperphosphatemia in Humans

verfasst von: Eugénie Koumakis, Catherine Cormier, Christian Roux, Karine Briot

Erschienen in: Calcified Tissue International | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Phosphate homeostasis involves several major organs that are the skeleton, the intestine, the kidney, and parathyroid glands. Major regulators of phosphate homeostasis are parathormone, fibroblast growth factor 23, 1,25-dihydroxyvitamin D, which respond to variations of serum phosphate levels and act to increase or decrease intestinal absorption and renal tubular reabsorption, through the modulation of expression of transcellular transporters at the intestinal and/or renal tubular level. Any acquired or genetic dysfunction in these major organs or regulators may induce hypo- or hyperphosphatemia. The causes of hypo- and hyperphosphatemia are numerous. This review develops the main causes of acquired and genetic hypo- and hyperphosphatemia.

Ruppe MD, Jan de Beur SM (2013) Disorders of phosphate homeostasis. In: Rosen CJ (ed) Primer on the Metabolic bone diseases and disorders of mineral metabolism. Wiley, Ames, pp 601–612CrossRef

Gaasbeek A, Meinders AE (2005) Hypophosphatemia: an update on its etiology and treatment. Am J Med 118:1094–1101. https://doi.org/10.1016/j.amjmed.2005.02.014CrossRefPubMed

Geerse DA, Schultz MJ (2016) Oxford textbook of critical care. Oxford University Press, Oxford

Betro MG, Pain RW (1972) Hypophosphataemia and hyperphosphataemia in a hospital population. Br Med J 1:273–276. https://doi.org/10.1136/bmj.1.5795.273CrossRefPubMedPubMedCentral

Halevy J, Bulvik S (1988) Severe hypophosphatemia in hospitalized patients. Arch Intern Med 148:153–155CrossRef

Prié D, Friedlander G (2010) Genetic disorders of renal phosphate transport. N Engl J Med 362:2399–2409. https://doi.org/10.1056/NEJMra0904186CrossRefPubMed

Baia LC, Heilberg IP, Navis G et al (2015) Phosphate and FGF-23 homeostasis after kidney transplantation. Nat Rev Nephrol 11:656–666. https://doi.org/10.1038/nrneph.2015.153CrossRefPubMed

Borowitz SM, Ghishan FK (1989) Phosphate transport in human jejunal brush-border membrane vesicles. Gastroenterology 96:4–10. https://doi.org/10.1016/0016-5085(89)90757-9CrossRefPubMed

Hattenhauer O, Traebert M, Murer H, Biber J (1999) Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake. Am J Physiol 277:G756–762. https://doi.org/10.1152/ajpgi.1999.277.4.G756CrossRefPubMed

10.

Katai K, Miyamoto K, Kishida S et al (1999) Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3. Biochem J 343(Pt 3):705–712CrossRef

11.

Xu H, Uno JK, Inouye M et al (2003) Regulation of intestinal NaPi-IIb cotransporter gene expression by estrogen. Am J Physiol Gastrointest Liver Physiol 285:G1317–1324. https://doi.org/10.1152/ajpgi.00172.2003CrossRefPubMed

12.

Xu H, Collins JF, Bai L et al (2001) Regulation of the human sodium-phosphate cotransporter NaP(i)-IIb gene promoter by epidermal growth factor. Am J Physiol Cell Physiol 280:C628–636. https://doi.org/10.1152/ajpcell.2001.280.3.C628CrossRefPubMed

13.

Shenolikar S, Voltz JW, Minkoff CM et al (2002) Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting. Proc Natl Acad Sci USA 99:11470–11475. https://doi.org/10.1073/pnas.162232699CrossRefPubMed

14.

Hoag HM, Martel J, Gauthier C, Tenenhouse HS (1999) Effects of Npt2 gene ablation and low-phosphate diet on renal Na(+)/phosphate cotransport and cotransporter gene expression. J Clin Invest 104:679–686. https://doi.org/10.1172/JCI7103CrossRefPubMedPubMedCentral

15.

Collins JF, Bulus N, Ghishan FK (1995) Sodium-phosphate transporter adaptation to dietary phosphate deprivation in normal and hypophosphatemic mice. Am J Physiol 268:G917–924. https://doi.org/10.1152/ajpgi.1995.268.6.G917CrossRefPubMed

16.

Taketani Y, Segawa H, Chikamori M et al (1998) Regulation of type II renal Na+-dependent inorganic phosphate transporters by 1,25-dihydroxyvitamin D3. Identification of a vitamin D-responsive element in the human NAPi-3 gene. J Biol Chem 273:14575–14581. https://doi.org/10.1074/jbc.273.23.14575CrossRefPubMed

17.

Alcalde AI, Sarasa M, Raldúa D et al (1999) Role of thyroid hormone in regulation of renal phosphate transport in young and aged rats. Endocrinology 140:1544–1551. https://doi.org/10.1210/endo.140.4.6658CrossRefPubMed

18.

Sorribas V, Markovich D, Verri T et al (1995) Thyroid hormone stimulation of Na/Pi-cotransport in opossum kidney cells. Pflugers Arch 431:266–271. https://doi.org/10.1007/bf00410200CrossRefPubMed

19.

Jankowski M, Biber J, Murer H (1999) PTH-induced internalization of a type IIa Na/Pi cotransporter in OK-cells. Pflug Arch 438:689–693. https://doi.org/10.1007/s004249900093CrossRef

20.

Murer H, Forster I, Hernando N et al (1999) Posttranscriptional regulation of the proximal tubule NaPi-II transporter in response to PTH and dietary P(i). Am J Physiol 277:F676–684. https://doi.org/10.1152/ajprenal.1999.277.5.F676CrossRefPubMed

21.

Schiavi SC, Kumar R (2004) The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 65:1–14. https://doi.org/10.1111/j.1523-1755.2004.00355.xCrossRefPubMed

22.

Guner YS, Kiela PR, Xu H et al (1999) Differential regulation of renal sodium-phosphate transporter by glucocorticoids during rat ontogeny. Am J Physiol 277:C884–890. https://doi.org/10.1152/ajpcell.1999.277.5.C884CrossRefPubMed

23.

Arar M, Zajicek HK, Elshihabi I, Levi M (1999) Epidermal growth factor inhibits Na-Pi cotransport in weaned and suckling rats. Am J Physiol 276:F72–78. https://doi.org/10.1152/ajprenal.1999.276.1.F72CrossRefPubMed

24.

Bacic D, Capuano P, Baum M et al (2005) Activation of dopamine D1-like receptors induces acute internalization of the renal Na+/phosphate cotransporter NaPi-IIa in mouse kidney and OK cells. Am J Physiol Renal Physiol 288:F740–747. https://doi.org/10.1152/ajprenal.00380.2004CrossRefPubMed

25.

Ambühl PM, Zajicek HK, Wang H et al (1998) Regulation of renal phosphate transport by acute and chronic metabolic acidosis in the rat. Kidney Int 53:1288–1298. https://doi.org/10.1046/j.1523-1755.1998.00901.xCrossRefPubMed

26.

Bergwitz C, Jüppner H (2009) Disorders of phosphate homeostasis and tissue mineralisation. Endocr Dev 16:133–156. https://doi.org/10.1159/000223693CrossRefPubMed

27.

Moallem E, Kilav R, Silver J, Naveh-Many T (1998) RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273:5253–5259. https://doi.org/10.1074/jbc.273.9.5253CrossRefPubMed

28.

Berndt TJ, Schiavi S, Kumar R (2005) “Phosphatonins” and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289:F1170–1182. https://doi.org/10.1152/ajprenal.00072.2005CrossRefPubMed

29.

Perwad F, Azam N, Zhang MYH et al (2005) Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358–5364. https://doi.org/10.1210/en.2005-0777CrossRefPubMed

30.

Liu ES, Martins JS, Raimann A et al (2016) 1,25-Dihydroxyvitamin D alone improves skeletal growth, microarchitecture, and strength in a murine model of XLH, despite enhanced FGF23 expression. J Bone Miner Res Res 31:929–939. https://doi.org/10.1002/jbmr.2783CrossRef

31.

Shimada T, Hasegawa H, Yamazaki Y et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435. https://doi.org/10.1359/JBMR.0301264CrossRefPubMed

32.

Rhee Y, Bivi N, Farrow E et al (2011) Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49:636–643. https://doi.org/10.1016/j.bone.2011.06.025CrossRefPubMedPubMedCentral

33.

Farrow EG, Yu X, Summers LJ et al (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 108:E1146–1155. https://doi.org/10.1073/pnas.1110905108CrossRefPubMed

34.

Xiao Z, Huang J, Cao L et al (2014) Osteocyte-specific deletion of Fgfr1 suppresses FGF23. PLoS ONE 9:e104154. https://doi.org/10.1371/journal.pone.0104154CrossRefPubMedPubMedCentral

35.

Omdahl JL, Morris HA, May BK (2002) Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 22:139–166. https://doi.org/10.1146/annurev.nutr.22.120501.150216CrossRefPubMed

36.

Berndt T, Craig TA, Bowe AE et al (2003) Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785–794. https://doi.org/10.1172/JCI18563CrossRefPubMedPubMedCentral

37.

Rowe PS, de Zoysa PA, Dong R et al (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54–68. https://doi.org/10.1006/geno.2000.6235CrossRefPubMed

38.

Carpenter TO, Ellis BK, Insogna KL et al (2005) Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90:1012–1020. https://doi.org/10.1210/jc.2004-0357CrossRefPubMed

39.

Marks J, Churchill LJ, Debnam ES, Unwin RJ (2008) Matrix extracellular phosphoglycoprotein inhibits phosphate transport. J Am Soc Nephrol JASN 19:2313–2320. https://doi.org/10.1681/ASN.2008030315CrossRefPubMed

40.

Lockitch G, Halstead AC, Albersheim S et al (1988) Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. Clin Chem 34:1622–1625CrossRef

41.

Shiber JR, Mattu A (2002) Serum phosphate abnormalities in the emergency department. J Emerg Med 23:395–400. https://doi.org/10.1016/s0736-4679(02)00578-4CrossRefPubMed

42.

Ravid M, Robson M (1976) Proximal myopathy caused by latrogenic phosphate depletion. JAMA 236:1380–1381CrossRef

43.

O’Connor LR, Wheeler WS, Bethune JE (1977) Effect of hypophosphatemia on myocardial performance in man. N Engl J Med 297:901–903. https://doi.org/10.1056/NEJM197710272971702CrossRefPubMed

44.

Amanzadeh J, Reilly RF (2006) Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2:136–148. https://doi.org/10.1038/ncpneph0124CrossRefPubMed

45.

Liamis G, Milionis HJ, Elisaf M (2010) Medication-induced hypophosphatemia: a review. QJM Mon J Assoc Physicians 103:449–459. https://doi.org/10.1093/qjmed/hcq039CrossRef

46.

Broman M, Wilsson AMJ, Hansson F, Klarin B (2017) Analysis of hypo- and hyperphosphatemia in an intensive care unit cohort. Anesth Analg 124:1897–1905. https://doi.org/10.1213/ANE.0000000000002077CrossRefPubMed

47.

Brautbar N, Leibovici H, Massry SG (1983) On the mechanism of hypophosphatemia during acute hyperventilation: evidence for increased muscle glycolysis. Miner Electrolyte Metab 9:45–50PubMed

48.

Marik PE, Bedigian MK (1996) Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study. Arch Surg Chic Ill 131:1043–1047. https://doi.org/10.1001/archsurg.1996.01430220037007CrossRef

49.

Seldin DW, Tarail R (1950) The metabolism of glucose and electrolytes in diabetic acidosis. J Clin Invest 29:552–565. https://doi.org/10.1172/JCI102293CrossRefPubMedPubMedCentral

50.

Gundersen K, Bradley RF, Marble A (1954) Serum phosphorus and potassium levels after intravenous administration of glucose; their use as diagnostic acids in diabetic and nondiabetic subjects with and without liver disease. N Engl J Med 250:547–554. https://doi.org/10.1056/NEJM195404012501302CrossRefPubMed

51.

Cohen J, Kogan A, Sahar G et al (2004) Hypophosphatemia following open heart surgery: incidence and consequences. Eur J Cardio-Thorac Surg 26:306–310. https://doi.org/10.1016/j.ejcts.2004.03.004CrossRef

52.

Pomposelli JJ, Pomfret EA, Burns DL et al (2001) Life-threatening hypophosphatemia after right hepatic lobectomy for live donor adult liver transplantation. Liver Transplant 7:637–642. https://doi.org/10.1053/jlts.2001.26287CrossRef

53.

Relman AS (1972) Metabolic consequences of acid-base disorders. Kidney Int 1:347–359. https://doi.org/10.1038/ki.1972.46CrossRefPubMed

54.

Rio A, Whelan K, Goff L et al (2013) Occurrence of refeeding syndrome in adults started on artificial nutrition support: prospective cohort study. BMJ Open. https://doi.org/10.1136/bmjopen-2012-002173CrossRefPubMedPubMedCentral

55.

Marinella MA (2003) The refeeding syndrome and hypophosphatemia. Nutr Rev 61:320–323. https://doi.org/10.1301/nr.2003.sept.320-323CrossRefPubMed

56.

Laaban JP, Grateau G, Psychoyos I et al (1989) Hypophosphatemia induced by mechanical ventilation in patients with chronic obstructive pulmonary disease. Crit Care Med 17:1115–1120. https://doi.org/10.1097/00003246-198911000-00005CrossRefPubMed

57.

Knochel JP, Caskey JH (1977) The mechanism of hypophosphatemia in acute heat stroke. JAMA 238:425–426CrossRef

58.

Brown GR, Greenwood JK (1994) Drug- and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill. Ann Pharmacother 28:626–632. https://doi.org/10.1177/106002809402800513CrossRefPubMed

59.

Elisaf MS, Siamopoulos KC (1997) Mechanisms of hypophosphataemia in alcoholic patients. Int J Clin Pract 51:501–503PubMed

60.

Palmer BF, Clegg DJ (2017) Electrolyte disturbances in patients with chronic alcohol-use disorder. N Engl J Med 377:1368–1377. https://doi.org/10.1056/NEJMra1704724CrossRefPubMed

61.

De Marchi S, Cecchin E, Basile A et al (1993) Renal tubular dysfunction in chronic alcohol abuse–effects of abstinence. N Engl J Med 329:1927–1934. https://doi.org/10.1056/NEJM199312233292605CrossRefPubMed

62.

Steiner M, Steiner B, Wilhelm S et al (2000) Severe hypophosphatemia during hematopoietic reconstitution after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 25:1015–1016. https://doi.org/10.1038/sj.bmt.1702407CrossRefPubMed

63.

Witteveen JE, van Thiel S, Romijn JA, Hamdy NAT (2013) Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol 168:R45–53. https://doi.org/10.1530/EJE-12-0528CrossRefPubMed

64.

Berger MM, Rothen C, Cavadini C, Chiolero RL (1997) Exudative mineral losses after serious burns: a clue to the alterations of magnesium and phosphate metabolism. Am J Clin Nutr 65:1473–1481. https://doi.org/10.1093/ajcn/65.5.1473CrossRefPubMed

65.

Pivnick EK, Kerr NC, Kaufman RA et al (1995) Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin Pediatr (Phila) 34:73–78. https://doi.org/10.1177/000992289503400202CrossRef

66.

Bouillon R, Carmeliet G (2018) Vitamin D insufficiency: definition, diagnosis and management. Best Pract Res Clin Endocrinol Metab 32:669–684. https://doi.org/10.1016/j.beem.2018.09.014CrossRefPubMed

67.

Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930. https://doi.org/10.1210/jc.2011-0385CrossRefPubMed

68.

Gallagher JC, Sai AJ (2010) Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab 95:2630–2633. https://doi.org/10.1210/jc.2010-0918CrossRefPubMedPubMedCentral

69.

Guillemant J, Taupin P, Le HT et al (1999) Vitamin D status during puberty in French healthy male adolescents. Osteoporos Int 10:222–225. https://doi.org/10.1007/s001980050219CrossRefPubMed

70.

Shah S, Chiang C, Sikaris K et al (2017) Serum 25-hydroxyvitamin D insufficiency in search of a bone disease. J Clin Endocrinol Metab 102:2321–2328. https://doi.org/10.1210/jc.2016-3189CrossRefPubMed

71.

Prentice A (2008) Vitamin D deficiency: a global perspective. Nutr Rev 66:S153–164. https://doi.org/10.1111/j.1753-4887.2008.00100.xCrossRefPubMed

72.

Shaker JL, Brickner RC, Findling JW et al (1997) Hypocalcemia and skeletal disease as presenting features of celiac disease. Arch Intern Med 157:1013–1016CrossRef

73.

Dibble JB, Sheridan P, Losowsky MS (1984) A survey of vitamin D deficiency in gastrointestinal and liver disorders. Q J Med 53:119–134PubMed

74.

Kumar R (1983) Hepatic and intestinal osteodystrophy and the hepatobiliary metabolism of vitamin D. Ann Intern Med 98:662–663. https://doi.org/10.7326/0003-4819-98-5-662CrossRefPubMed

75.

Peterson LA, Zeng X, Caufield-Noll CP et al (2016) Vitamin D status and supplementation before and after bariatric surgery: a comprehensive literature review. Surg Obes Relat Dis 12:693–702. https://doi.org/10.1016/j.soard.2016.01.001CrossRefPubMed

76.

Wang Z, Lin YS, Zheng XE et al (2012) An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol Pharmacol 81:498–509. https://doi.org/10.1124/mol.111.076356CrossRefPubMedPubMedCentral

77.

Kitanaka S, Takeyama K, Murayama A et al (1998) Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 338:653–661. https://doi.org/10.1056/NEJM199803053381004CrossRefPubMed

78.

Cheng JB, Levine MA, Bell NH et al (2004) Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA 101:7711–7715. https://doi.org/10.1073/pnas.0402490101CrossRefPubMed

79.

Thacher TD, Fischer PR, Singh RJ et al (2015) CYP2R1 Mutations impair generation of 25-hydroxyvitamin D and cause an atypical form of vitamin D deficiency. J Clin Endocrinol Metab 100:E1005–1013. https://doi.org/10.1210/jc.2015-1746CrossRefPubMedPubMedCentral

80.

Fraser D, Kooh SW, Kind HP et al (1973) Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med 289:817–822. https://doi.org/10.1056/NEJM197310182891601CrossRefPubMed

81.

Chen H, Hewison M, Hu B, Adams JS (2003) Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: a cause of vitamin D resistance. Proc Natl Acad Sci USA 100:6109–6114. https://doi.org/10.1073/pnas.1031395100CrossRefPubMed

82.

Brooks MH, Bell NH, Love L et al (1978) Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med 298:996–999. https://doi.org/10.1056/NEJM197805042981804CrossRefPubMed

83.

Fujita T, Nomura M, Okajima S, Furuya H (1980) Adult-onset vitamin D-resistant osteomalacia with the unresponsiveness to parathyroid hormone. J Clin Endocrinol Metab 50:927–931. https://doi.org/10.1210/jcem-50-5-927CrossRefPubMed

84.

Roizen JD, Li D, O’Lear L et al (2018) CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest 128:1913–1918. https://doi.org/10.1172/JCI98680CrossRefPubMedPubMedCentral

85.

Griebeler ML, Kearns AE, Ryu E et al (2015) Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010). Bone 73:1–7. https://doi.org/10.1016/j.bone.2014.12.003CrossRefPubMed

86.

Bilezikian JP, Bandeira L, Khan A, Cusano NE (2018) Hyperparathyroidism. Lancet Lond Engl 391:168–178. https://doi.org/10.1016/S0140-6736(17)31430-7CrossRef

87.

Baloch ZW, Livolsi VA (2015) Parathyroids: morphology and pathology. In: Bilezikian JP, Marcus R, Levine MA, Marocci C, Silverberg SJ (eds) The parathyroids, 3rd edn. Williams and Wilkins Sydney, Sydney, pp 23–36CrossRef

88.

Pearce SH, Williamson C, Kifor O et al (1996) A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335:1115–1122. https://doi.org/10.1056/NEJM199610103351505CrossRefPubMed

89.

Horwitz MJ, Tedesco MB, Sereika SM et al (2011) A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover. J Bone Miner Res 26:2287–2297. https://doi.org/10.1002/jbmr.415CrossRefPubMedPubMedCentral

90.

Horwitz MJ, Tedesco MB, Sereika SM et al (2005) Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res 20:1792–1803. https://doi.org/10.1359/JBMR.050602CrossRefPubMed

91.

Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373–379. https://doi.org/10.1056/NEJMcp042806CrossRefPubMed

92.

Horwitz MJ, Hodak SP, Stewart AF (2013) Non-parathyroid hypercalcemia. In: Clifford J, Rosen MD (eds) Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th edn. American Society for Bone and Mineral Research, Washington, DC, pp 562–570CrossRef

93.

Fraser WD (2009) Hyperparathyroidism. Lancet 374:145–158. https://doi.org/10.1016/S0140-6736(09)60507-9CrossRefPubMed

94.

Isakova T, Wahl P, Vargas GS et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378. https://doi.org/10.1038/ki.2011.47CrossRefPubMedPubMedCentral

95.

Evenepoel P, Meijers BKI, de Jonge H et al (2008) Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol CJASN 3:1829–1836. https://doi.org/10.2215/CJN.01310308CrossRefPubMed

96.

Green J, Debby H, Lederer E et al (2001) Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 60:1182–1196. https://doi.org/10.1046/j.1523-1755.2001.0600031182.xCrossRefPubMed

97.

Higgins RM, Richardson AJ, Endre ZH et al (1990) Hypophosphataemia after renal transplantation: relationship to immunosuppressive drug therapy and effects on muscle detected by 31P nuclear magnetic resonance spectroscopy. Nephrol Dial Transplant 5:62–68. https://doi.org/10.1093/ndt/5.1.62CrossRefPubMed

98.

Brasier AR, Nussbaum SR (1988) Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 84:654–660. https://doi.org/10.1016/0002-9343(88)90100-3CrossRefPubMed

99.

Hamilton AJ, Bingham C, McDonald TJ et al (2014) The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotype. J Med Genet 51:165–169. https://doi.org/10.1136/jmedgenet-2013-102066CrossRefPubMed

100.

Folpe AL, Fanburg-Smith JC, Billings SD et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1–30. https://doi.org/10.1097/00000478-200401000-00001CrossRefPubMed

101.

Boland JM, Tebben PJ, Folpe AL (2018) Phosphaturic mesenchymal tumors: what an endocrinologist should know. J Endocrinol Invest 41:1173–1184. https://doi.org/10.1007/s40618-018-0849-5CrossRefPubMed

102.

Folpe AL (2019) Phosphaturic mesenchymal tumors: a review and update. Semin Diagn Pathol 36:260–268. https://doi.org/10.1053/j.semdp.2019.07.002CrossRefPubMed

103.

Jonsson KB, Zahradnik R, Larsson T et al (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663. https://doi.org/10.1056/NEJMoa020881CrossRefPubMed

104.

Yamazaki Y, Okazaki R, Shibata M et al (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960. https://doi.org/10.1210/jc.2002-021105CrossRefPubMed

105.

Lee J-C, Su S-Y, Changou CA et al (2016) Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29:1335–1346. https://doi.org/10.1038/modpathol.2016.137CrossRefPubMed

106.

Elderman JH, Wabbijn M, de Jongh F (2016) Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin’s lymphoma. BMJ Case Rep. https://doi.org/10.1136/bcr-2015-213954CrossRefPubMedPubMedCentral

107.

Leaf DE, Pereira RC, Bazari H, Jüppner H (2013) Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab 98:887–891. https://doi.org/10.1210/jc.2012-3473CrossRefPubMedPubMedCentral

108.

Nakahama H, Nakanishi T, Uno H et al (1995) Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int 55:38–40. https://doi.org/10.1159/000282746CrossRefPubMed

109.

Huang LL, Lee D, Troster SM et al (2018) A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant 33:1628–1635. https://doi.org/10.1093/ndt/gfx310CrossRefPubMed

110.

Ifie E, Oyibo S, Joshi H, Akintade O (2019) Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction. Endocrinol Diabetes Metab Case Rep. https://doi.org/10.1530/EDM-19-0065CrossRefPubMedPubMedCentral

111.

Bishay RH, Ganda K, Seibel MJ (2017) Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther Adv Endocrinol Metab 8:14–19. https://doi.org/10.1177/2042018816678363CrossRefPubMed

112.

Wolf M, White KE (2014) Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23:411–419. https://doi.org/10.1097/01.mnh.0000447020.74593.6fCrossRefPubMedPubMedCentral

113.

Beck L, Soumounou Y, Martel J et al (1997) Pex/PEX tissue distribution and evidence for a deletion in the 3’ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99:1200–1209. https://doi.org/10.1172/JCI119276CrossRefPubMedPubMedCentral

114.

Beck-Nielsen SS, Mughal Z, Haffner D et al (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 14:58. https://doi.org/10.1186/s13023-019-1014-8CrossRefPubMedPubMedCentral

115.

Beck-Nielsen SS, Brock-Jacobsen B, Gram J et al (2009) Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 160:491–497. https://doi.org/10.1530/EJE-08-0818CrossRefPubMed

116.

Endo I, Fukumoto S, Ozono K et al (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62:811–816. https://doi.org/10.1507/endocrj.EJ15-0275CrossRefPubMed

117.

Rafaelsen S, Johansson S, Ræder H, Bjerknes R (2016) Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 174:125–136. https://doi.org/10.1530/EJE-15-0515CrossRefPubMed

118.

Bowe AE, Finnegan R, Jan de Beur SM et al (2001) FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284:977–981. https://doi.org/10.1006/bbrc.2001.5084CrossRefPubMed

119.

Benet-Pagès A, Lorenz-Depiereux B, Zischka H et al (2004) FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455–462. https://doi.org/10.1016/j.bone.2004.04.002CrossRefPubMed

120.

Rowe PSN (2012) Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 22:61–86. https://doi.org/10.1615/critreveukargeneexpr.v22.i1.50CrossRefPubMedPubMedCentral

121.

Yuan B, Feng JQ, Bowman S et al (2013) Hexa-D-arginine treatment increases 7B2·PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype. J Bone Miner Res 28:56–72. https://doi.org/10.1002/jbmr.1738CrossRefPubMedPubMedCentral

122.

Bai X, Miao D, Xiao S et al (2016) CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest 126:667–680. https://doi.org/10.1172/JCI81928CrossRefPubMedPubMedCentral

123.

Murthy AS (2009) X-linked hypophosphatemic rickets and craniosynostosis. J Craniofac Surg 20:439–442. https://doi.org/10.1097/SCS.0b013e31819b9868CrossRefPubMed

124.

Connor J, Olear EA, Insogna KL et al (2015) Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab 100:3625–3632. https://doi.org/10.1210/JC.2015-2199CrossRefPubMedPubMedCentral

125.

Liang G, Katz LD, Insogna KL et al (2009) Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. Calcif Tissue Int 85:235–246. https://doi.org/10.1007/s00223-009-9270-6CrossRefPubMedPubMedCentral

126.

Che H, Roux C, Etcheto A et al (2016) Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol 174:325–333. https://doi.org/10.1530/EJE-15-0661CrossRefPubMed

127.

ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348. https://doi.org/10.1038/81664CrossRef

128.

White KE, Jonsson KB, Carn G et al (2001) The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497–500. https://doi.org/10.1210/jcem.86.2.7408CrossRefPubMed

129.

Shimada T, Muto T, Urakawa I et al (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179–3182. https://doi.org/10.1210/endo.143.8.8795CrossRefPubMed

130.

Clinkenbeard EL, White KE (2017) Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics. Bone 102:31–39. https://doi.org/10.1016/j.bone.2017.01.034CrossRefPubMedPubMedCentral

131.

Imel EA, Hui SL, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520–526. https://doi.org/10.1359/jbmr.070107CrossRefPubMed

132.

Clinkenbeard EL, Farrow EG, Summers LJ et al (2014) Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res 29:361–369. https://doi.org/10.1002/jbmr.2049CrossRefPubMedPubMedCentral

133.

Econs MJ, McEnery PT, Lennon F, Speer MC (1997) Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 100:2653–2657. https://doi.org/10.1172/JCI119809CrossRefPubMedPubMedCentral

134.

Brownstein CA, Adler F, Nelson-Williams C et al (2008) A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 105:3455–3460. https://doi.org/10.1073/pnas.0712361105CrossRefPubMed

135.

Toyosawa S, Shintani S, Fujiwara T et al (2001) Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. J Bone Miner Res 16:2017–2026. https://doi.org/10.1359/jbmr.2001.16.11.2017CrossRefPubMed

136.

Feng JQ, Ward LM, Liu S et al (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310–1315. https://doi.org/10.1038/ng1905CrossRefPubMedPubMedCentral

137.

Lorenz-Depiereux B, Bastepe M, Benet-Pagès A et al (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248–1250. https://doi.org/10.1038/ng1868CrossRefPubMedPubMedCentral

138.

Addison WN, Azari F, Sørensen ES et al (2007) Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 282:15872–15883. https://doi.org/10.1074/jbc.M701116200CrossRefPubMed

139.

Lorenz-Depiereux B, Schnabel D, Tiosano D et al (2010) Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86:267–272. https://doi.org/10.1016/j.ajhg.2010.01.006CrossRefPubMedPubMedCentral

140.

Levy-Litan V, Hershkovitz E, Avizov L et al (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:273–278. https://doi.org/10.1016/j.ajhg.2010.01.010CrossRefPubMedPubMedCentral

141.

Rutsch F, Ruf N, Vaingankar S et al (2003) Mutations in ENPP1 are associated with “idiopathic” infantile arterial calcification. Nat Genet 34:379–381. https://doi.org/10.1038/ng1221CrossRefPubMed

142.

Tagliabracci VS, Engel JL, Wiley SE et al (2014) Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci USA 111:5520–5525. https://doi.org/10.1073/pnas.1402218111CrossRefPubMed

143.

Simpson MA, Hsu R, Keir LS et al (2007) Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development. Am J Hum Genet 81:906–912. https://doi.org/10.1086/522240CrossRefPubMedPubMedCentral

144.

Fradin M, Stoetzel C, Muller J et al (2011) Osteosclerotic bone dysplasia in siblings with a Fam20C mutation. Clin Genet 80:177–183. https://doi.org/10.1111/j.1399-0004.2010.01516.xCrossRefPubMed

145.

Rafaelsen SH, Raeder H, Fagerheim AK et al (2013) Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. J Bone Miner Res 28:1378–1385. https://doi.org/10.1002/jbmr.1850CrossRefPubMed

146.

Takeyari S, Yamamoto T, Kinoshita Y et al (2014) Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome. Bone 67:56–62. https://doi.org/10.1016/j.bone.2014.06.026CrossRefPubMed

147.

Collins MT, Singer FR, Eugster E (2012) McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis 7(1):S4. https://doi.org/10.1186/1750-1172-7-S1-S4CrossRefPubMedPubMedCentral

148.

Riminucci M, Collins MT, Fedarko NS et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692. https://doi.org/10.1172/JCI18399CrossRefPubMedPubMedCentral

149.

Weinstein LS, Shenker A, Gejman PV et al (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688–1695. https://doi.org/10.1056/NEJM199112123252403CrossRefPubMed

150.

Menascu S, Donner EJ (2008) Linear nevus sebaceous syndrome: case reports and review of the literature. Pediatr Neurol 38:207–210. https://doi.org/10.1016/j.pediatrneurol.2007.10.012CrossRefPubMed

151.

Ovejero D, Lim YH, Boyce AM et al (2016) Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. Osteoporos Int 27:3615–3626. https://doi.org/10.1007/s00198-016-3702-8CrossRefPubMedPubMedCentral

152.

Lim YH, Ovejero D, Sugarman JS et al (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet 23:397–407. https://doi.org/10.1093/hmg/ddt429CrossRefPubMed

153.

Tieder M, Modai D, Samuel R et al (1985) Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 312:611–617. https://doi.org/10.1056/NEJM198503073121003CrossRefPubMed

154.

Tieder M, Modai D, Shaked U et al (1987) “Idiopathic” hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect. N Engl J Med 316:125–129. https://doi.org/10.1056/NEJM198701153160302CrossRefPubMed

155.

Bergwitz C, Roslin NM, Tieder M et al (2006) SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 78:179–192. https://doi.org/10.1086/499409CrossRefPubMed

156.

Lorenz-Depiereux B, Benet-Pages A, Eckstein G et al (2006) Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78:193–201. https://doi.org/10.1086/499410CrossRefPubMed

157.

Dasgupta D, Wee MJ, Reyes M et al (2014) Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J Am Soc Nephrol JASN 25:2366–2375. https://doi.org/10.1681/ASN.2013101085CrossRefPubMed

158.

Tencza AL, Ichikawa S, Dang A et al (2009) Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3/type IIc sodium-phosphate cotransporter: presentation as hypercalciuria and nephrolithiasis. J Clin Endocrinol Metab 94:4433–4438. https://doi.org/10.1210/jc.2009-1535CrossRefPubMedPubMedCentral

159.

Prié D, Huart V, Bakouh N et al (2002) Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347:983–991. https://doi.org/10.1056/NEJMoa020028CrossRefPubMed

160.

Magen D, Berger L, Coady MJ et al (2010) A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med 362:1102–1109. https://doi.org/10.1056/NEJMoa0905647CrossRefPubMed

161.

Schlingmann KP, Ruminska J, Kaufmann M et al (2016) Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia. J Am Soc Nephrol JASN 27:604–614. https://doi.org/10.1681/ASN.2014101025CrossRefPubMed

162.

Karim Z, Gérard B, Bakouh N et al (2008) NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 359:1128–1135. https://doi.org/10.1056/NEJMoa0802836CrossRefPubMed

163.

Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA (1995) Osteomalacia associated with adult Fanconi’s syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 43:479–490. https://doi.org/10.1111/j.1365-2265.1995.tb02621.xCrossRef

164.

Yang Y-S, Peng C-H, Sia S-K, Huang C-N (2007) Acquired hypophosphatemia osteomalacia associated with Fanconi’s syndrome in Sjögren’s syndrome. Rheumatol Int 27:593–597. https://doi.org/10.1007/s00296-006-0257-6CrossRefPubMed

165.

Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G (2003) Drug-induced Fanconi’s syndrome. Am J Kidney Dis 41:292–309. https://doi.org/10.1053/ajkd.2003.50037CrossRefPubMed

166.

Hall AM, Bass P, Unwin RJ (2014) Drug-induced renal Fanconi syndrome. QJM Mon J Assoc Physicians 107:261–269. https://doi.org/10.1093/qjmed/hct258CrossRef

167.

Mateo L, Holgado S, Mariñoso ML et al (2016) Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol 35:1271–1279. https://doi.org/10.1007/s10067-014-2627-xCrossRefPubMed

168.

Kazama I, Matsubara M, Michimata M et al (2004) Adult onset Fanconi syndrome: extensive tubulo-interstitial lesions and glomerulopathy in the early stage of Chinese herbs nephropathy. Clin Exp Nephrol 8:283–287. https://doi.org/10.1007/s10157-004-0296-9CrossRefPubMed

169.

Messiaen T, Deret S, Mougenot B et al (2000) Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 79:135–154. https://doi.org/10.1097/00005792-200005000-00002CrossRef

170.

Stokes MB, Valeri AM, Herlitz L et al (2016) Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era. J Am Soc Nephrol JASN 27:1555–1565. https://doi.org/10.1681/ASN.2015020185CrossRefPubMed

171.

Vignon M, Javaugue V, Alexander MP et al (2017) Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. Leukemia 31:123–129. https://doi.org/10.1038/leu.2016.195CrossRefPubMed

172.

Manohar S, Nasr SH, Leung N (2018) Light chain cast nephropathy: practical considerations in the management of myeloma Kidney-what we know and what the future may hold. Curr Hematol Malig Rep 13:220–226. https://doi.org/10.1007/s11899-018-0451-0CrossRefPubMed

173.

Cherqui S, Courtoy PJ (2017) The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives. Nat Rev Nephrol 13:115–131. https://doi.org/10.1038/nrneph.2016.182CrossRefPubMed

174.

Anglani F, Gianesello L, Beara-Lasic L, Lieske J (2019) Dent disease: a window into calcium and phosphate transport. J Cell Mol Med 23:7132–7142. https://doi.org/10.1111/jcmm.14590CrossRefPubMedPubMedCentral

175.

Blanchard A, Curis E, Guyon-Roger T et al (2016) Observations of a large Dent disease cohort. Kidney Int 90:430–439. https://doi.org/10.1016/j.kint.2016.04.022CrossRefPubMed

176.

Levin-Iaina N, Dinour D (2012) Renal disease with OCRL1 mutations: Dent-2 or Lowe syndrome? J Pediatr Genet 1:3–5. https://doi.org/10.3233/PGE-2012-002CrossRefPubMedPubMedCentral

177.

Lichter-Konecki U, Broman KW, Blau EB, Konecki DS (2001) Genetic and physical mapping of the locus for autosomal dominant renal Fanconi syndrome, on chromosome 15q15.3. Am J Hum Genet 68:264–268. https://doi.org/10.1086/316923CrossRefPubMed

178.

Tieder M, Arie R, Modai D et al (1988) Elevated serum 1,25-dihydroxyvitamin D concentrations in siblings with primary Fanconi’s syndrome. N Engl J Med 319:845–849. https://doi.org/10.1056/NEJM198809293191307CrossRefPubMed

179.

Tolaymat A, Sakarcan A, Neiberger R (1992) Idiopathic Fanconi syndrome in a family. Part I. Clinical aspects. J Am Soc Nephrol JASN 2:1310–1317PubMed

180.

Klootwijk ED, Reichold M, Helip-Wooley A et al (2014) Mistargeting of peroxisomal EHHADH and inherited renal Fanconi’s syndrome. N Engl J Med 370:129–138. https://doi.org/10.1056/NEJMoa1307581CrossRefPubMed

181.

Lim C, Tan HK, Kaushik M (2017) Hypophosphatemia in critically ill patients with acute kidney injury treated with hemodialysis is associated with adverse events. Clin Kidney J 10:341–347. https://doi.org/10.1093/ckj/sfw120CrossRefPubMedPubMedCentral

182.

Wong PS, Barclay PL, Newman MJ, Johns EJ (1994) The influence of acetazolamide and amlodipine on the intracellular sodium content of rat proximal tubular cells. Br J Pharmacol 112:881–886. https://doi.org/10.1111/j.1476-5381.1994.tb13162.xCrossRefPubMedPubMedCentral

183.

Mechanick JI, Liu K, Nierman DM, Stein A (2006) Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury. J Spinal Cord Med 29:406–412. https://doi.org/10.1080/10790268.2006.11753890CrossRefPubMedPubMedCentral

184.

Body JJ, Lortholary A, Romieu G et al (1999) A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res Off J Am Soc Bone Miner Res 14:1557–1561. https://doi.org/10.1359/jbmr.1999.14.9.1557CrossRef

185.

Hu MI, Glezerman IG, Leboulleux S et al (2014) Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99:3144–3152. https://doi.org/10.1210/jc.2014-1001CrossRefPubMedPubMedCentral

186.

Watkins KR, Rogers JE, Atkinson B (2015) Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency. Support Care Cancer 23:1657–1662. https://doi.org/10.1007/s00520-014-2521-8CrossRefPubMed

187.

Tataranni T, Biondi G, Cariello M et al (2011) Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression. Am J Transplant Surg 11:1656–1664. https://doi.org/10.1111/j.1600-6143.2011.03590.xCrossRef

188.

Kempe DS, Dërmaku-Sopjani M, Fröhlich H et al (2010) Rapamycin-induced phosphaturia. Nephrol Dial Transplant 25:2938–2944. https://doi.org/10.1093/ndt/gfq172CrossRefPubMed

189.

Bech AP, Hoorn EJ, Zietse R et al (2018) Yield of diagnostic tests in unexplained renal hypophosphatemia: a case series. BMC Nephrol 19:220. https://doi.org/10.1186/s12882-018-1017-zCrossRefPubMedPubMedCentral

190.

Skeid MS, Pedersen-Bjergaard U, Kristensen PL, Brandi L (2016) NSAID-induced symptomatic hypophosphataemia. Br J Clin Pharmacol 82:1399–1401. https://doi.org/10.1111/bcp.13061CrossRefPubMedPubMedCentral

191.

Manghat P, Sodi R, Swaminathan R (2014) Phosphate homeostasis and disorders. Ann Clin Biochem 51:631–656. https://doi.org/10.1177/0004563214521399CrossRefPubMed

192.

Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet Lond Engl 2:309–310. https://doi.org/10.1016/s0140-6736(75)92736-1CrossRef

193.

Nilsson I-L, Norenstedt S, Granath F et al (2016) FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery 159:211–217. https://doi.org/10.1016/j.surg.2015.06.057CrossRefPubMed

194.

Witteveen JE, van Lierop AH, Papapoulos SE, Hamdy NAT (2012) Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? Eur J Endocrinol 166:55–60. https://doi.org/10.1530/EJE-11-0523CrossRefPubMed

195.

Saab G, Whooley MA, Schiller NB, Ix JH (2010) Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study. Am J Kidney Dis 56:496–505. https://doi.org/10.1053/j.ajkd.2010.03.030CrossRefPubMedPubMedCentral

196.

Jung S-Y, Kim H, Park S et al (2016) Electrolyte and mineral disturbances in septic acute kidney injury patients undergoing continuous renal replacement therapy. Medicine (Baltimore) 95:e4542. https://doi.org/10.1097/MD.0000000000004542CrossRef

197.

Jung S-Y, Kwon J, Park S et al (2018) Phosphate is a potential biomarker of disease severity and predicts adverse outcomes in acute kidney injury patients undergoing continuous renal replacement therapy. PLoS ONE 13:e0191290. https://doi.org/10.1371/journal.pone.0191290CrossRefPubMedPubMedCentral

198.

Casais M-N, Rosa-Diez G, Pérez S et al (2009) Hyperphosphatemia after sodium phosphate laxatives in low risk patients: prospective study. World J Gastroenterol 15:5960–5965. https://doi.org/10.3748/wjg.15.5960CrossRefPubMedPubMedCentral

199.

Lopes AA, Tong L, Thumma J et al (2012) Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis Off J Natl Kidney Found 60:90–101. https://doi.org/10.1053/j.ajkd.2011.12.025CrossRef

200.

Davidson MB, Thakkar S, Hix JK et al (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116:546–554. https://doi.org/10.1016/j.amjmed.2003.09.045CrossRefPubMed

201.

Vervloet MG, van Ballegooijen AJ (2018) Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int 93:1060–1072. https://doi.org/10.1016/j.kint.2017.11.036CrossRefPubMed

202.

Levin A, Bakris GL, Molitch M et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38. https://doi.org/10.1038/sj.ki.5002009CrossRefPubMed

203.

Fusaro M, Holden R, Lok C et al (2019) Phosphate and bone fracture risk in chronic kidney disease patients. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfz196CrossRefPubMed

204.

Mannstadt M, Bilezikian JP, Thakker RV et al (2017) Hypoparathyroidism. Nat Rev Dis Primer 3:17080. https://doi.org/10.1038/nrdp.2017.80CrossRef

205.

Clarke BL, Brown EM, Collins MT et al (2016) Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 101:2284–2299. https://doi.org/10.1210/jc.2015-3908CrossRefPubMedPubMedCentral

206.

Goswami R, Millo T, Mishra S et al (2014) Expression of osteogenic molecules in the caudate nucleus and gray matter and their potential relevance for Basal Ganglia calcification in hypoparathyroidism. J Clin Endocrinol Metab 99:1741–1748. https://doi.org/10.1210/jc.2013-3863CrossRefPubMedPubMedCentral

207.

Shoback DM, Bilezikian JP, Costa AG et al (2016) Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab 101:2300–2312. https://doi.org/10.1210/jc.2015-3909CrossRefPubMed

208.

Bilezikian JP, Khan A, Potts JT et al (2011) Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 26:2317–2337. https://doi.org/10.1002/jbmr.483CrossRefPubMedPubMedCentral

209.

Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res Off J Am Soc Bone Miner Res 30:1738–1744. https://doi.org/10.1002/jbmr.2501CrossRef

210.

Steen O., Khan A. (2015) Role of Magnesium in Parathyroid Physiology. In: Brandi M., Brown E. (eds), Hypoparathyroidism. Springer, Milano.

211.

Barbour GL, Coburn JW, Slatopolsky E et al (1981) Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med 305:440–443. https://doi.org/10.1056/NEJM198108203050807CrossRefPubMed

212.

Grunenwald S, Tack I, Chauveau D et al (2011) Impact of growth hormone hypersecretion on the adult human kidney. Ann Endocrinol 72:485–495. https://doi.org/10.1016/j.ando.2011.08.001CrossRef

213.

Ramnitz MS, Gafni RI, Collins MT (1993) Hyperphosphatemic familial tumoral calcinosis. In: Adam MP, Ardinger HH, Pagon RA, et al. (eds), GeneReviews®. University of Washington, Seattle.

214.

Chakhtoura M, Ramnitz MS, Khoury N et al (2018) Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature. Osteoporos Int 29:1987–2009. https://doi.org/10.1007/s00198-018-4574-xCrossRefPubMed

215.

Roberts MS, Burbelo PD, Egli-Spichtig D et al (2018) Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. J Clin Invest 128:5368–5373. https://doi.org/10.1172/JCI122004CrossRefPubMedPubMedCentral

216.

Whyte MP (2016) Hypophosphatasia-aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 12:233–246. https://doi.org/10.1038/nrendo.2016.14CrossRefPubMed

Titel: The Causes of Hypo- and Hyperphosphatemia in Humans
verfasst von: Eugénie Koumakis
Catherine Cormier
Christian Roux
Karine Briot
Publikationsdatum: 13.04.2020
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 1/2021
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-020-00664-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Phosphate as a Signaling Molecule

Phosphate Metabolism in Health and Disease

Tumor-Induced Osteomalacia

Congenital Conditions of Hypophosphatemia Expressed in Adults

Congenital Conditions of Hypophosphatemia in Children